A collaborative research project between Aston University in Birmingham, UK and London-based healthcare company Insight Health Limited is to tackle the serious problem of healthcare associated infection (HAI).
The project - a Knowledge Transfer Partnership funded by the Department of Health and Insight Health - aims to develop a non-toxic product for eliminating spores of Clostridium difficile from the hospital setting.
C. difficile is the most common HAI in the UK accounting for approximately 50,000 infections annually and is associated with around 6,500 deaths. There is a clear social benefit in developing novel cleaning strategies that will contribute to reducing the level of infection, which in turn would reduce the mortality rate.
The development and implementation of an effective, non-toxic cleaning strategy may also block the route of transfer (or contamination) from one location to another, so reducing the incidence of infection.
It has also been calculated that each infection costs approximately £4,000 to treat; making a reduction in infection rates have a significant financial impact on hospital trusts. In addition, the patients' stay in hospital would be reduced, which would minimise the potential for acquiring other infections and increase the overall throughput of patients due to improved bed availability.
Set up in 2000 to specifically targe HAIs, Insight Health's aim is to develop further products that will reduce hospital acquired infections, targeting C. difficile - a major cause of death within the young and elderly in hospitals - as a priority.
‘We already have the route to market and appropriate infrastructure but require a centre of expertise to drive novel product development in this area,’ says London-based Insight Health's Managing Director, John Rawlinson. ‘The KTP will be the first stage in allowing us the creation of this capability, through the development of an extensive knowledge base of microbiological information.’
Drawing on the expertise of Aston Microbiologists Dr Tony Worthington, Dr Laura Wheeldon and Professor Peter Lambert from the University’s School of Life & Health Sciences, the partnership will allow the development of a new 'germination solution' to help eliminate C. difficile and allow swift transfer from drawing board to hospital implementation. In addition, Aston will provide access to appropriate laboratory facilities that will allow the safe development of the product and the capability of converting the results of laboratory scale trials into safe, commercially viable products. In the process of developing these innovative products, the company will be able to forge closer links with the healthcare and manufacturing sectors. The microbiologists already have a wealth of research experience associated with the diagnosis and prevention of other hospital acquired infections, including MRSA, bacterial biofilms, catheter related sepsis and acinetobacter.
‘This KTP collaboration not only allows the Microbiology team to develop innovative products for use within the healthcare setting, which will hopefully contribute to reducing the C. difficile burden, but also to continue to undertake relevant research in line with Aston's 2012 strategy,’ said Dr Tony Worthington.
For further press information please contact Sally Finn on 0121 204 4552 or email email@example.com.
Insight Health Limited is based in London, visit www.insight-health.net for further information.